Assertio Therapeutics, Inc. (formally Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 72.31M; Volume: 120.71K; AvgVol 3m: 654.78K; Beta: –;
P/E: –; EPS: -2.11; EPS growth quarter/prev quarter: -65.90%;
EPS growth this year: -634.30%; EPS growth past 5 years: -28.50%;
EPS ttm: -2.11;
P/S: 0.47; P/B: 0.81; P/Cashflow: ; P/FCF: ;
Sales: 155.92M; Sales growth quarter/prev quarter: -64.00%; Sales growth past 5 years: -10.10%;
Gross Margin: 92.70%; Profit Margin: ; Operating Margin: -98.30%;
ROA – return on assets: -39.50%; ROE – return on equity: -153.60%; LT Debt/Equity: 01.08; Total Debt/Equity: 1.17;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 3.60%; Insider Transactions:-0.42%;
Institutional Ownership: 59.30%; Institutional Transactions: 16.46%;
Data update: 07/10/2020.